乳癌市场 - 三阴性-KOL的洞察

本报告提供三阴性乳癌市场相关调查，现在及未来的治疗流程，已上市及开发平台的治疗药趋势等彙整资讯。

目录

摘要整理

三阴性乳癌的现在及未来的治疗流程

调查目的

三阴性乳癌

• 已上市药物
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Talzenna (talazoparib; Pfizer)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
• 开发平台药物
  • Bavencio (avelumab; Merck Group)
  • veliparib (ABT-888; AbbVie)
  • Zejula (niraparib; GlaxoSmithKline)
  • ipatasertib (Roche) and capivasertib (AstraZeneca)
  • Piqray (alpelisib; Novartis)
  • Cosela (trilaciclib; G1 Therapeutics)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
• 影响治疗的一般未来趋势
  • 重要的洞察概要

附录

• KOL详细内容
  • 北美的KOL
  • 欧洲的KOL

What's exciting oncologists in triple-negative cancer therapy? What clinical benefits do KOLs cite for AstraZeneca/Daiichi Sankyo's pipeline datopotamab deruxtecan and why will the readouts of the BEGONIA trial be significant? Why do experts believe the mechanism of action of G1 Therapeutics' late-stage CDK4/CDK6 inhibitor Cosela could lead to improved outcomes? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Table of Contents

Executive summary

Triple-negative breast cancer current and future treatment algorithm

Research objectives

Triple-negative breast cancer

• Marketed drugs
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Talzenna (talazoparib; Pfizer)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
• Pipeline drugs
  • Bavencio (avelumab; Merck Group)
  • veliparib (ABT-888; AbbVie)
  • Zejula (niraparib; GlaxoSmithKline)
  • ipatasertib (Roche) and capivasertib (AstraZeneca)
  • Piqray (alpelisib; Novartis)
  • Cosela (trilaciclib; G1 Therapeutics)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
• General future trends impacting treatment
  • Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe